Urologic cancers, which include prostate, bladder, and kidney malignancies, pose significant global health challenges due to ...

In April, 2025, Demis Hassabis, the Nobel Prize-winning CEO of Google DeepMind, appeared on the US television show 60 Minutes and suggested that all diseases could be curable with the help of ...

Trial data showed the drug dramatically reduced cancer progression risk in certain patients, supporting Celcuity’s plans to ...

From overlooked diagnostics and underused screening to AI potential and workforce gaps, these are the innovation challenges in oncology that cancer leaders told Becker’s they feel deserve more ...

Signals suggest the drugs could improve on the standard of care, but the market may not make it easy for another megablockbuster to rise to the top.

With Virgin shares holding nicely at cruising altitude, is now the right time for private oncology drug developer Qbiotics to ...

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

A potential target for experimental drugs that block PRMT5—a naturally occurring enzyme some tumors rely more on for survival ...

New capital, maturing pipelines, and a more global R&D mindset are pushing valuations higher, even as competition tightens.

Pfizer Inc. has completed the previously announced global, ex-China, licensing agreement with 3SBio Inc., which grants Pfizer exclusive rights for the development, manufacturing and commercialization ...

As Merck gears up for its Q2 earnings, all eyes are on Keytruda, its oncology superstar. Keytruda, accounting for nearly half of Merck’s pharma sales, is anticipated to report Q2 sales of $7.90 ...